CAMP4 THERAPEUTICS (CAMP) is trading down at $3.99 (-0.25%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $350.0K | $652.0K | $3.50M |
| Growth (year over year) | — | +86.3% | +436.5% |
| Operating income | −$51.9M | −$53.1M | −$52.6M |
| Operating margin | −14822.6% | −8142.3% | −1502.4% |
| Net income | −$49.3M | −$51.8M | −$80.4M |
| Net margin | −14083.1% | −7943.4% | −2298.5% |
| EPS (diluted) | −$124.80 | −$11.04 | −$2.65 |
| Balance sheet | |||
| Cash and equivalents | $38.4M | $64.0M | $109.5M |
| Total assets | $54.9M | $78.3M | $117.8M |
| Total liabilities | $16.5M | $15.2M | $70.1M |
| Shareholders' equity | −$123.7M | $63.1M | $47.7M |
| Cash flow | |||
| Operating cash flow | −$44.2M | −$45.6M | −$29.6M |
| Capital expenditure | $678.0K | $441.0K | $279.0K |
| Free cash flow | −$44.8M | −$46.0M | −$29.8M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $858.0K | $1.50M | $795.0K | $348.0K | $1.29M | $1.78M |
| Growth (year over year) | −100.0% | — | — | — | — | — | +50.8% | +18.8% |
| Operating income | −$13.5M | — | −$13.1M | −$13.0M | −$13.7M | −$12.8M | −$13.1M | −$13.4M |
| Operating margin | — | — | −1526.8% | −870.3% | −1717.1% | −3671.3% | −1010.1% | −752.1% |
| Net income | −$13.5M | — | −$12.4M | −$12.6M | −$15.1M | −$40.3M | −$18.3M | −$33.5M |
| Net margin | — | — | −1449.1% | −840.8% | −1899.2% | −11575.9% | −1416.6% | −1884.8% |
| EPS (diluted) | −$24.19 | — | −$0.62 | −$0.62 | −$0.55 | −$0.86 | −$0.32 | −$0.58 |
| Balance sheet | ||||||||
| Cash and equivalents | $2.53M | $64.0M | $49.3M | $39.1M | $75.3M | $109.5M | $99.2M | $86.4M |
| Total assets | $21.4M | $78.3M | $62.8M | $51.3M | $86.4M | $117.8M | $105.5M | $93.4M |
| Total liabilities | $18.2M | $15.2M | $11.2M | $11.3M | $27.7M | $70.1M | $74.6M | $94.1M |
| Shareholders' equity | −$159.0M | $63.1M | $51.6M | $40.0M | $58.7M | $47.7M | $30.9M | −$693.0K |
| Cash flow | ||||||||
| Operating cash flow | −$9.69M | — | −$14.3M | −$10.3M | −$11.2M | $6.29M | −$11.0M | −$12.7M |
| Capital expenditure | $0 | — | $279.0K | $0 | $0 | $0 | $0 | $129.0K |
| Free cash flow | −$9.69M | — | −$14.6M | −$10.3M | −$11.2M | $6.29M | −$11.0M | −$12.8M |
From CAMP4 THERAPEUTICS's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
‘Watermelons’: Zack Polanski and the rise of the ‘green outside, red inside’ eco-populists
Author Russell Warfield argues the Green leader’s brand of politics is not new but has evolved in the party over time
Watermelons: the term used to describe the members of the Green party of England …
Gunnison Copper CEO on $8m Nuton deal; permitting on track at Johnson Camp
Gunnison Copper CEO on $8m Nuton deal; permitting on track at Johnson Camp
Gunnison Copper reaches deal with Nuton to expand Johnson Camp mine plan
Gunnison Copper reaches deal with Nuton to expand Johnson Camp mine plan